SMS Pharmaceuticals Limited (NSE: SMSPHARMA) reports 6% YoY revenue growth in Q1 FY27, driven by high-value APIs and structural improvements.
SMS Pharmaceuticals Limited (SMSPHARMA) reports FY26 PAT up 48% to ₹102 crore, driven by margin expansion and backward integration.